Now I have a thorough understanding of the paper. Let me produce the consolidated review.

## Summary

This paper proposes MMFRL, a framework that (1) pretrains molecular graph encoders via a modified relational learning loss aligning graph embeddings with similarity distributions from auxiliary modalities (NMR, image, SMILES, fingerprint), and (2) fuses multiple pretrained encoders at early, intermediate, or late stages for downstream molecular property prediction. On 11 MoleculeNet benchmarks, MMFRL variants achieve the best results on 9 out of 11 tasks.

## Strengths

- **Strong empirical performance across diverse MoleculeNet tasks.** MMFRL_intermediate achieves the best results on 7 of 11 benchmarks, and MMFRL_late wins on 2 more, together covering 9/11 tasks. Gains are substantial on several tasks: BACE (95.1±1.0 vs. next-best Uni-Mol 85.7±0.2), BBBP (95.4±0.7 vs. DMPNN 91.9±3.0), and ESOL (RMSE 0.730 vs. Uni-Mol 0.788). The consistent pattern across both classification and regression tasks adds credibility.

- **Systematic comparison of fusion stages with analysis.** The paper provides a principled comparison of early, intermediate, and late fusion for molecular property prediction — a design question largely unexplored in prior work. The post-hoc analysis (t-SNE solubility gradients for ESOL, learned weight distributions for Lipo) gives concrete insight into why intermediate fusion works well (complementary modality interactions during fine-tuning) and how late fusion automatically identifies dominant modalities.

- **Multimodal pretraining helps even when individual modalities underperform.** A compelling case is Clintox: no individual unimodality-pretrained model beats the no-pretraining baseline (90.6), yet MMFRL_intermediate reaches 93.4±1.1 — demonstrating that fusion genuinely compensates for weak individual signals rather than simply ensembling strong ones.

- **Rich modality set.** Incorporating NMR_spectrum, NMR_peak, image, fingerprint, and SMILES (five modalities from four distinct families) is more comprehensive than prior multimodal molecular work.

## Weaknesses

### Major

- **Suspiciously low baseline scores undermine the claimed superiority over existing methods.** The DMPNN backbone (no pretraining) achieves 91.9±3.0 on BBBP, yet several published methods report far lower scores in the paper's table: AttentiveFP (64.3±1.8), GraphCL (67.5±3.3), InfoGraph (69.2±0.8), MolCLR (73.3±1.0). The gap between DMPNN (same backbone as MMFRL) and AttentiveFP on BBBP is >27 points — too large to be explained by architectural differences alone. The paper does not describe how baselines were configured, whether the same scaffold splits were used, or whether hyperparameter tuning was attempted. This makes it impossible to determine whether MMFRL's advantages reflect genuine methodological improvement or merely better-tuned training.

### Minor

- **Missing implementation details prevent reproducibility.** The paper does not specify: the DMPNN encoder architecture (number of layers, hidden dimensions, pooling method), how each modality's "fixed embedding" \(z_i^R\) is computed (e.g., Morgan fingerprint radius, SMILES tokenization/encoding scheme, NMR preprocessing), training hyperparameters (learning rate, batch size, number of epochs, optimizer), or the number of scaffold splits/seeds. These are standard reporting requirements and should be included.

- **No ablation isolating the relational learning component.** The paper never directly compares MRL against the original relational learning loss or against a standard contrastive loss (e.g., InfoNCE) in the same pretraining setup. Since the MRL loss is cross-entropy between two softmax-normalized similarity distributions (essentially knowledge distillation from one embedding space to another), it is unclear whether the continuous metric is what drives gains, or simply having any multimodal alignment objective. Theorem 1 states the optimum condition for cross-entropy minimization, not a convergence guarantee — the "convergence" framing is overstated.

- **Comparison among fusion methods is confounded.** Early fusion uses fixed equal weights (0.2), intermediate fusion uses a learned MLP, and late fusion learns instance-specific weights. These differ in both fusion stage and model complexity. The paper acknowledges the limitation of early fusion's fixed weights ("for simplicity") but does not control for it — e.g., a learnable-weight early fusion or a fixed-weight late fusion would isolate the effect of fusion stage from capacity.

- **Statistical significance is not established.** Standard deviations are large on several metrics (e.g., unimodality Clintox ±6.5, unimodality MUV ±5.2, MMFRL_early BBBP ±5.0, MMFRL_early Clintox ±6.8). While the MMFRL fusion variants have tighter variance on most tasks, the paper does not report confidence intervals or significance tests, making it unclear which comparisons are statistically reliable.

### Trivial

- The Thalidomide enantiomer example in the introduction is a good motivation for continuous similarity, but the paper never returns to demonstrate that MMFRL distinguishes such cases. This is a missed opportunity for a concrete case study but does not affect the paper's validity.

## Nice-to-Haves

- Direct comparison of MRL vs. the original RL loss and a contrastive loss (InfoNCE) under the same pretraining setup would cleanly demonstrate that the continuous metric matters.
- Including a controlled fusion comparison (learnable early fusion weights, fixed late fusion weights) would strengthen the analysis of fusion stage versus model capacity.
- Atom-level or substructure-level similarity (mentioned in the discussion as future work) would connect more directly to the enantiomer motivation.

## Removed Points

These points are flagged to be removed — treat them with caution.

- **Critic's claim that "AttentiveFP achieves only 64.3% on BBBP, whereas the original paper reports ≈91.8% under the same scaffold split."** The specific value 91.8% cannot be verified from the paper's content, and the source of the critic's claim is external. However, the core concern — that baseline scores are implausibly low relative to the DMPNN backbone — is kept as a Major weakness above, independently of any specific published number.
- **"No confidence intervals or significance tests" moved to Minor.** The critic frames this as a structural flaw, but it is a common gap in ML benchmark papers and does not invalidate results on its own.
- **"Graph-level vs. node-level similarity" moved to Nice-to-Haves.** The paper explicitly discusses this as future work; demanding it as a current weakness is scope creep.
- **"The paper never returns to Thalidomide example" is real but Trivial** — it is a motivation example, not an evaluated claim.
- **Strength Finder's claim that "Theorem 1 proves convergence of this metric"** is inaccurate (the theorem only characterizes the optimum), so this strength is dropped from the main review.

## Novel Insights

None beyond the paper's own contributions.

## Suggestions

- **Run all baselines using the same DMPNN backbone** with careful hyperparameter tuning (e.g., Chemprop's built-in optimization) and report those results alongside the paper's current numbers. At minimum, disclose which scaffold splits were used for each baseline and whether official implementations with recommended settings were used.
- **Add an ablation comparing MRL against (a) no pretraining, (b) the original RL loss, (c) InfoNCE contrastive loss** with the same multimodal alignment setup. This is the cleanest test of whether the continuous metric adds value.
- **Provide full implementation details** — encoder architecture, modality embedding procedures, hyperparameters, number of seeds — either in the main text or supplementary material.
- **Include significance tests** (e.g., paired bootstrap) or at minimum note which comparisons are not statistically reliable given overlapping error bars.

## Score and Decision

The paper has a sensible motivation and its framework is reasonably constructed. The main empirical results are promising, and the systematic comparison of fusion stages adds practical value. However, the baseline tuning concern is a genuine weakness that prevents full confidence in the claimed superiority over existing methods. With proper baseline tuning and ablations, this could be a solid contribution. In its current form, I recommend rejection, but encourage resubmission after addressing the baseline concern.

MY FINAL SCORE: <pineapple>5.0</pineapple>
MY FINAL DECISION: <orange>Reject</orange>